Literature DB >> 35585949

Transition from epoprostenol to selexipag in a patient with systemic sclerosis and pulmonary hypertension during the postoperative period of colon cancer surgery: A case report.

Takuma Tsuzuki Wada1, Kazuhiro Yokota1, Shinichiro Iida2, Yuki Kanno3, Nozomi Shinozuka3, Kojiro Sato1,4, Yu Funakubo Asanuma1, Keiji Yamamoto2, Toshihide Mimura1.   

Abstract

Introduction: Most pulmonary vasodilators are administered orally; however, in patients with pulmonary hypertension undergoing gastrointestinal surgery, a switch to parenteral drugs is needed. Parenteral pulmonary vasodilators carry a risk of infection and reduced quality of life owing to long-term central venous catheterization; therefore, it is preferable to switch them to oral vasodilators after surgery. Here, we present the case of a patient with systemic sclerosis complicated by pulmonary hypertension and colon cancer, for which treatment was successfully switched from epoprostenol to selexipag postoperatively. Case Description: A 59-year-old woman, who was diagnosed with mixed group I and III pulmonary hypertension and systemic sclerosis, was on oral triple pulmonary vasodilators for pulmonary hypertension and Raynaud's phenomenon. She was diagnosed as having colon cancer 3 months before admission. Despite the severe pulmonary condition and treatment with oral triple pulmonary vasodilators, colon cancer resection surgery was performed with the management for pulmonary hypertension through multidisciplinary treatments in collaboration with cardiology specialists. Medications for patients with pulmonary hypertension undergoing gastrointestinal surgery need to be switched from oral vasodilators to epoprostenol perioperatively. On postoperative day 19, 0.4 mg/day of selexipag was administered with epoprostenol. Subsequently, the epoprostenol dosage was gradually decreased, and selexipag was increased. On postoperative day 30, the dose of selexipag was increased to 1.2 mg/day and epoprostenol was discontinued. The patient was discharged on postoperative day 40.
Conclusion: In our case, transition from epoprostenol to selexipag contributed to a more useful management strategy for systemic sclerosis and pulmonary hypertension in the postoperative period.
© The Author(s) 2021.

Entities:  

Keywords:  Pulmonary hypertension; epoprostenol; perioperative management; selexipag; systemic sclerosis

Year:  2021        PMID: 35585949      PMCID: PMC9109508          DOI: 10.1177/23971983211063711

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  5 in total

1.  Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.

Authors:  Kenichi Yanaka; Alicia Guillien; Thibaud Soumagne; Justin Benet; Nicolas Piliero; François Picard; Christophe Pison; Olivier Sitbon; Hélène Bouvaist; Bruno Degano
Journal:  Eur Respir J       Date:  2020-06-18       Impact factor: 16.671

2.  Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.

Authors:  Kishan S Parikh; Sean Doerfler; Nicholas Shelburne; Karla Kennedy; Jordan Whitson; Talal Dahhan; Terry Fortin; Sudarshan Rajagopal
Journal:  J Cardiovasc Pharmacol       Date:  2020-04       Impact factor: 3.105

3.  Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.

Authors:  Melvyn Rubenfire; Mark D Huffman; Sangeetha Krishnan; James R Seibold; Elena Schiopu; Vallerie V McLaughlin
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

4.  Scheduled perioperative switch from oral sildenafil to intravenous epoprostenol in a patient with Eisenmenger syndrome undergoing a sigmoidectomy.

Authors:  Kiyoshi Moriyama; Koji Uzawa; Takehiko Iijima; Mariko Kotani; Kumi Moriyama; Yuki Ohashi; Toru Satoh; Tomoko Yorozu
Journal:  J Clin Anesth       Date:  2012-07-02       Impact factor: 9.452

5.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.